SOURCE: Caris Life Sciences

Caris Life Sciences

November 29, 2011 15:34 ET

Caris Target Now™ Targets Cancer Treatment Selection

IRVING, TX--(Marketwire - Nov 29, 2011) - As research into cancer care advances, physicians can now take better aim in the care of their cancer patients, using evidence-based molecular profiling to help determine which cancer therapies are more likely to be effective and which therapies are likely to be ineffective.

A new evidence-based molecular profiling system -- called Caris Target Now™ -- is bringing about dramatic changes in the personalization of cancer care.

No two cancers are alike and cancer treatment plans shouldn't be either. Treatment that works well for one person may be ineffective for another, because each patient's cancer has different genetics. Caris Target Now™ makes it possible to detect those differences, match a tumor's genetics with specific drugs more likely to be effective, and flag therapies with less chance of working.

Personalized cancer treatment like this can increase quality of life, uncover treatments previously not considered, and cut healthcare costs.

One multicenter study conducted by Caris Life Sciences, and published in the Journal of Clinical Oncology, showed that Caris Target Now™ molecular profiling increased progression free survival from various cancers, including late-stage cancer, in 27 percent of 86 patients studied who had their therapy selected this way, versus the previous therapy on which they had progressed.

Sandeep K. Reddy, MD, oncology expert and clinical associate professor of medicine, Geffen/UCLA School of Medicine, discusses Caris Target Now™, and Sandra Fehrman, a cancer patient, explains how this technology helped to extend and enhance her life, in this moving video.

For more information about the role of molecular profiling in cancer therapy selection, patients can visit and healthcare professionals may be interested in

Contact Information